Imerys S.A (NK) Fair Value & Analysis

Basic Materials · FR · Market cap €1.8B

Below-average quality, screening 29% undervalued on our models.

What matters now

• The model range is unusually wide (€12.16 to €49.64). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Our model range runs from €12.16 (bear) to €49.64 (bull), base €30.90. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 40/100 (below-average quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range €19.17 – €35.11 · fair‑value band €12.16 – €49.64 · the €23.98 price screens below the €30.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Imerys S.A (NK) currently trades at €23.98, while our model-based Fair Value estimate is €30.90, implying the stock looks roughly 28.9% undervalued today. The Quality Score stands at 40/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Imerys S.A generated revenue of €3.3B at a net margin of -12.9%. Revenue declined 4.1% year over year. It earns a return on equity of -13.9%. Net debt stands at €1.9B. Fundamentals as of Aug 13, 2026

Our scenario range runs from €12.16 (bear case) to €49.64 (bull case); at €23.98, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -68% fair-value upside, at 29%, NK screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (€20.56) versus Earnings-Based (€2.60). Highest evidence: Rev-Margin DCF (74).

Key figures & financial health

Quality Score breakdown

About the company

Imerys S.A. engages in the supply of specialty minerals for various industries across Europe, the Middle East, Africa, Asia Pacific, and America.

Full company description

Imerys S.A. engages in the supply of specialty minerals for various industries across Europe, the Middle East, Africa, Asia Pacific, and America. The company offers performance minerals, such as additives for plastics, paints and coatings, filtration and life sciences, ceramics, and building products; specialty minerals used as processing aids for extreme work conditions, including refractory, foundry, abrasives, and building chemistry; and graphite and carbon minerals for energy transition and mobile energy markets. It also provides minerals, such as andalusite, ball clay, bentonite, calcium carbonate, carbon black, chamotte, diatomite, feldspar, fused alumina, graphite, halloysite, kaolin, lithium, mica, moler, mullite, perlite, quartz, talc, zeolite, zirconia, and wollastonite. The company serves various markets, such as abrasives, advanced ceramics, animal care, batteries and fuel cells, building materials, ceramics, component manufacturing, cosmetics and personal care, crop production, food and beverage, health, pharmaceuticals and biotechnology, home care, infrastructure and utilities, investment casting, pulp and packaging, and rubber markets. The company was incorporated in 1880 and is headquartered in Paris, France. Imerys S.A. is a subsidiary of Belgian Securities BV.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Imerys S.A reported revenue of €3.4B in FY2025 versus €3.7B in FY2021, a compound −2.0%/yr. Reported net income was −€409M in FY2025.

Watch NK: get an alert when its fair value changes →

Peer Group

Specialty Chemicals · 671 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Basic Materials stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.